Tags

Type your tag names separated by a space and hit enter

The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications.
Bone. 2013 Jun; 54(2):222-9.BONE

Abstract

The identification of elevated circulating levels of the osteocytic protein fibroblast growth factor 23 (FGF23) in patients with chronic kidney disease (CKD), along with recent data linking these values to the pathogenesis of secondary hyperparathyroidism and to systemic complications, has changed the approach to the pathophysiology and treatment of disordered bone and mineral metabolism in renal failure. It now appears that osteocyte biology is altered very early in the course of CKD and these changes have implications for bone biology, as well as for progressive cardiovascular and renal disease. Since circulating FGF23 values are influenced by therapies used to treat secondary hyperparathyroidism, the effects of different therapeutic paradigms on FGF23 have important implications for mineral metabolism as well as for morbidity and mortality. Further studies are critically needed to identify the initial trigger for abnormalities of skeletal mineralization and turnover as well as the potential effects that current therapeutic options may have on osteocyte biology.

Authors+Show Affiliations

David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. kwesseling@mednet.ucla.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23079136

Citation

Wesseling-Perry, Katherine, and Harald Jüppner. "The Osteocyte in CKD: New Concepts Regarding the Role of FGF23 in Mineral Metabolism and Systemic Complications." Bone, vol. 54, no. 2, 2013, pp. 222-9.
Wesseling-Perry K, Jüppner H. The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications. Bone. 2013;54(2):222-9.
Wesseling-Perry, K., & Jüppner, H. (2013). The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications. Bone, 54(2), 222-9. https://doi.org/10.1016/j.bone.2012.10.008
Wesseling-Perry K, Jüppner H. The Osteocyte in CKD: New Concepts Regarding the Role of FGF23 in Mineral Metabolism and Systemic Complications. Bone. 2013;54(2):222-9. PubMed PMID: 23079136.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications. AU - Wesseling-Perry,Katherine, AU - Jüppner,Harald, Y1 - 2012/10/16/ PY - 2012/06/07/received PY - 2012/10/01/revised PY - 2012/10/04/accepted PY - 2012/10/20/entrez PY - 2012/10/20/pubmed PY - 2013/9/27/medline SP - 222 EP - 9 JF - Bone JO - Bone VL - 54 IS - 2 N2 - The identification of elevated circulating levels of the osteocytic protein fibroblast growth factor 23 (FGF23) in patients with chronic kidney disease (CKD), along with recent data linking these values to the pathogenesis of secondary hyperparathyroidism and to systemic complications, has changed the approach to the pathophysiology and treatment of disordered bone and mineral metabolism in renal failure. It now appears that osteocyte biology is altered very early in the course of CKD and these changes have implications for bone biology, as well as for progressive cardiovascular and renal disease. Since circulating FGF23 values are influenced by therapies used to treat secondary hyperparathyroidism, the effects of different therapeutic paradigms on FGF23 have important implications for mineral metabolism as well as for morbidity and mortality. Further studies are critically needed to identify the initial trigger for abnormalities of skeletal mineralization and turnover as well as the potential effects that current therapeutic options may have on osteocyte biology. SN - 1873-2763 UR - https://www.unboundmedicine.com/medline/citation/23079136/The_osteocyte_in_CKD:_new_concepts_regarding_the_role_of_FGF23_in_mineral_metabolism_and_systemic_complications_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S8756-3282(12)01316-6 DB - PRIME DP - Unbound Medicine ER -